The Truth About GLP-1 Weight Management Through Concierge Medicine

GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — have transformed what’s clinically achievable in weight management. The average weight loss in clinical trials for these medications exceeds what any previous pharmacological intervention produced. For patients who are appropriate candidates, these medications represent a genuine change in the landscape of what’s possible.

The results from clinical trials don’t automatically translate to individual patient outcomes — and the difference between the average trial participant result and what a given patient actually achieves is largely determined by the clinical support surrounding the medication, not the medication itself.

At My Concierge MD in Beverly Hills, Dr. David Nazarian provides GLP-1 weight management as part of a concierge medicine model that wraps comprehensive, personalized clinical oversight around every patient’s treatment — producing a fundamentally different experience than the telehealth prescription-and-ship model that has proliferated alongside GLP-1 medication demand.

How GLP-1 Medications Work — More Than Just Appetite

GLP-1 (glucagon-like peptide-1) is a hormone naturally produced in the intestine in response to food intake. GLP-1 receptor agonists mimic and amplify this hormone’s effects through several simultaneous mechanisms:

• Appetite reduction: GLP-1 receptors in the hypothalamus signal satiety — the experience of being full. Activating these receptors pharmacologically produces a reduced appetite that most patients describe as qualitatively different from dieting: not willpower suppressing hunger, but hunger that is genuinely diminished.
• Slowed gastric emptying: GLP-1 slows how quickly food moves from the stomach into the small intestine. This prolongs the feeling of fullness after eating and reduces the caloric intake that naturally follows when food is processed more quickly.
• Insulin regulation: GLP-1 stimulates insulin release in response to blood glucose — and crucially, this effect is glucose-dependent, meaning it occurs when blood sugar is elevated and diminishes as blood sugar normalizes. This is the mechanism that makes these medications effective for diabetes management without producing hypoglycemia.
• Central dopamine effects: Research is increasingly demonstrating that GLP-1 receptor activation affects the dopamine reward system — reducing the hedonic drive to eat beyond hunger and, in some cases, reducing the compulsive pull toward food that characterizes disordered eating patterns.

Understanding that GLP-1 medications work through multiple simultaneous mechanisms — not simply “appetite suppression” — clarifies why they produce the outcomes they do and why patients who don’t fully suppress appetite still achieve significant results through the gastric emptying and metabolic mechanisms.

The Concierge Difference in GLP-1 Management

The clinical experience of GLP-1 medications varies dramatically based on how they’re managed. Patients who receive a prescription without ongoing clinical oversight often experience suboptimal outcomes: side effects that are manageable with appropriate guidance but cause treatment abandonment without it, dose escalation that occurs too quickly for their individual tolerance, and inadequate attention to the behavioral and nutritional changes that determine what happens to weight after medication is eventually reduced or stopped.

Dr. Nazarian’s concierge approach means GLP-1 management includes:

• Comprehensive baseline evaluation: Metabolic panel, thyroid function, cardiac assessment, and a thorough history before medication begins — establishing both candidacy and the baseline that subsequent monitoring tracks against.
• Individualized dosing protocols: Not a standard titration schedule, but a schedule calibrated to each patient’s response, side effect tolerance, and rate of weight loss.
• Regular monitoring appointments: Blood work, vital signs, and direct conversation about how the medication is working — and real-time protocol adjustments when the situation warrants them.
• Nutritional and behavioral guidance: The patient’s diet quality during treatment determines what the body composition changes look like and what the weight trajectory looks like after the medication is tapered. This guidance doesn’t come with a prescription alone.

The Long-Term Maintenance Question

Clinical trials data consistently shows that the majority of patients who stop GLP-1 medications regain significant weight within the following year. This isn’t a medication failure — it’s the natural result of stopping a medication that was actively managing a chronic condition. Weight management for patients with metabolic dysfunction is a long-term clinical relationship, not a course of treatment with a defined end point.

Dr. Nazarian’s GLP-1 management includes a long-term plan — for patients who will maintain ongoing low-dose medication, for those who will taper to lifestyle maintenance, and for those who need to understand what the maintenance phase actually requires before they begin treatment. The plan is made at the start, not discovered at the end.

Schedule Your Consultation at My Concierge MD

Dr. David Nazarian and the My Concierge MD team are located at 9301 Wilshire Boulevard, Suite 405A, in Beverly Hills, serving patients throughout Los Angeles, Bel Air, Century City, West Hollywood, Santa Monica, and beyond. Call (310) 299-8959 to schedule your consultation. GLP-1 medication with comprehensive clinical oversight is a different experience than a prescription with a shipping confirmation.

This blog is educational. Weight management involves individual medical factors. All treatment decisions should be made following a comprehensive evaluation with a qualified physician.

Who Is a Candidate for GLP-1 Therapy Through My Concierge MD

Current FDA approval for GLP-1 weight management medications (semaglutide at the Wegovy dose, tirzepatide as Zepbound) covers adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition (type 2 diabetes, hypertension, dyslipidemia, sleep apnea, or cardiovascular disease). The candidacy assessment at My Concierge MD evaluates the patient’s full clinical picture — not just BMI — to determine the most appropriate medication, dose, and monitoring protocol.

Patients who have tried GLP-1 medications through telehealth platforms without adequate clinical oversight and found either poor results or significant side effects they couldn’t manage often find the concierge model produces a different experience. The clinical attention to dose titration, side effect management, and behavioral support that the concierge relationship provides is what was missing from the previous experience — not the medication itself.

The concierge membership at My Concierge MD provides direct access to Dr. Nazarian — same-day appointments, direct phone and text communication, house calls when appropriate, and the kind of provider relationship that produces a genuinely different standard of care. For Los Angeles and Beverly Hills patients accustomed to managing their health on their own schedule, this access model is as meaningful as the clinical expertise behind it.

Medically reviewed by David Nazarian, MD on October 28, 2026